Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05046314 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | PHASE2 | COMPLETED | 15 | — | — | Mar 12, 2024 | Feb 5, 2025 | Mar 19, 2026 | 8 | China |
Determination of the Objective Response Rate of all patients by IRC
| Arm | Type | Description |
|---|---|---|
| TK216+Vincristin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TK216+Vincristin | BIOLOGICAL | TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle. |
Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible for this study: 1. Willing to sign the informed consent form. 2. Participants with relapsed or refractory ES (including ESFT, except Ewing-like sarcoma) confirmed by cytohistology or molecular biology...